Cook Jennifer E. 4

4 · BridgeBio Pharma, Inc. · Filed Jun 24, 2026

AI-generated summary of this filing

Updated Jun 24, 2026

BridgeBio (BBIO) Director Jennifer Cook Exercises Options, Sells Shares

What Happened

Jennifer E. Cook, a director of BridgeBio Pharma (BBIO), exercised two stock option tranches on June 24, 2026 (20,000 shares at $8.45 and 17,167 shares at $16.75), paying $456,547 in exercise price. She sold 37,167 of the shares acquired from those exercises the same day at $70.00 for $2,601,690. Separately, on June 23, 2026 she sold 2,196 shares in the open market at $68.57 for $150,580. On June 22, 2026 she was also granted 3,990 and 5,277 restricted stock units (RSUs) (total 9,267 RSUs) that vest on June 22, 2027.

Key Details

Transaction dates and prices:
- 2026-06-24: Exercised 20,000 shares @ $8.45 (cost $169,000) and 17,167 shares @ $16.75 (cost $287,547); sold 37,167 shares @ $70.00 (proceeds $2,601,690).
- 2026-06-23: Sold 2,196 shares @ $68.57 (proceeds $150,580) under a Rule 10b5-1 plan.
- 2026-06-22: Granted 3,990 RSUs and 5,277 RSUs (total 9,267 RSUs) — RSUs vest 6/22/2027.
Total sales proceeds reported: about $2,752,270; total exercise cost reported: $456,547.
The filing includes derivative "disposed" line items at $0.00 for 37,167 shares on 6/24 (these relate to the option exercises/settlement reported on the same form).
The 6/23 sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 16, 2026 (per footnote).
Shares owned after the transactions are not specified in the Form 4 excerpt provided.
Filing date: Form filed 2026-06-24 covering transactions 2026-06-22 to 2026-06-24; filing appears timely.

Context

Exercising options and selling the resulting shares the same day is commonly a cashless exercise/sale pattern (here exercises and sales occurred on 6/24). That typically converts option holdings into cash but does not by itself indicate the director's longer-term view.
RSU grants vest in the future (6/22/2027) and are contingent on continued board service per the footnotes.
The 10b5-1 plan used for the 6/23 sale indicates the sale was pre-planned, which is routine for insiders and intended to avoid timing concerns.

Form 4

Period: 2026-06-22

Director

Transactions

Award
Common Stock
[F1][F2]
2026-06-22+3,990→ 10,579 total
Sale
Common Stock
[F3]
2026-06-23$68.57/sh−2,196$150,580→ 8,383 total
Exercise/Conversion
Common Stock
[F3]
2026-06-24$8.45/sh+20,000$169,000→ 28,383 total
Exercise/Conversion
Common Stock
[F3]
2026-06-24$16.75/sh+17,167$287,547→ 45,550 total
Sale
Common Stock
[F3]
2026-06-24$70.00/sh−37,167$2,601,690→ 8,383 total
Award
Stock Option (Right to Buy)
[F4]
2026-06-22+5,277→ 5,277 total
Exercise: $68.92Exp: 2036-06-21→ Common Stock (5,277 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F3][F5]
2026-06-24−20,000→ 19,000 total
Exercise: $8.45Exp: 2032-06-22→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F3][F6]
2026-06-24−17,167→ 17,167 total
Exercise: $16.75Exp: 2033-06-21→ Common Stock (17,167 underlying)

Footnotes (6)

[F1]Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
[F4]The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
[F5]1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
[F6]1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Signature

/s/ Will Solis, Attorney-in-Fact|2026-06-24

1 file